Puma Biotechnology Inc. (PBYI)

24.56
0.88 3.72
NASDAQ : Health Technology
Prev Close 23.68
Open 23.92
Day Low/High 23.86 / 25.10
52 Wk Low/High 17.60 / 94.85
Volume 668.89K
Avg Volume 1.39M
Exchange NASDAQ
Shares Outstanding 38.13M
Market Cap 961.76M
EPS -7.80
P/E Ratio N/A
Div & Yield N.A. (N.A)

PBYI SHAREHOLDER ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Puma Biotechnology, Inc. And A Lead Plaintiff Deadline Of July 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Thursday's 'Triathlon of Terror' Is Overblown: Cramer's 'Mad Money' Recap (Wednesday 6/7/17)

Comey's testimony? U.K. elections? Eurozone news? These can be new buying opportunities, says Jim Cramer.

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Sirius XM Radio, Shopify, Teledoc, Tyson Foods: 'Mad Money' Lightning Round

Jim Cramer takes a closer look at Sirius XM Radio, Shopify, Teledoc, Sarepta Therapeutics, Pilgrim's Pride.

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

Brand Loyalty Elusive for Apparel Retailers: Cramer's 'Mad Money' Recap (Tuesday 6/6/17)

It's not about fashion missteps, says Jim Cramer. Who cares what the products look like if there's no one in the stores?

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders Of Puma Biotechnology, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

'APHINITY' Study Spells Major Trouble for Roche, Another Win for Puma Bio

This will be the investors' verdict on the results of Roche's APHINITY study of Perjeta in adjuvant breast cancer treatment that were released Monday morning.

Puma Biotechnology Announces Positive PB272 Phase II Data From TBCRC 022 Trial In Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases At The 2017 ASCO Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the presentation of positive results from an ongoing Phase II clinical trial (Translational Breast Cancer Research Consortium TBCRC 022) of...

PBYI INVESTOR ALERT: The Law Offices Of Vincent Wong Reminds Investors Of A Class Action Involving Puma Biotechnology, Inc. And A Lead Plaintiff Deadline Of July 7, 2017

The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the United States District Court for the Central District of California on behalf of investors who purchased Puma Biotechnology, Inc.

Puma Biotechnology To Present At The Jefferies 2017 Healthcare Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders Of Puma Biotechnology, Inc. Of A Class Action Lawsuit And A Lead Plaintiff Deadline Of July 7, 2017

The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Puma Biotechnology, Inc.

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

Bullish Puma Investor Talks Neratinb FDA Panel Win, Next Steps and Takeout Potential

A head-to-head showdown in metastatic breast cancer and the Roche APHINITY data are next key events for Puma.

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Biotech Movers: Positive Phase Three Results For Roclatan Send Aerie Shares Soaring

Aerie Pharmaceuticals, BioCryst Pharmaceuticals and GW Pharmaceuticals were among the biotech movers in premarket trading on Thursday.

Puma Biotechnology Receives FDA Advisory Committee Support For Neratinib

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, today announced that the U.

This Market is Now Overbought; Waiting for Another Pullback

This Market is Now Overbought; Waiting for Another Pullback

Despite the good action in the indices, I'm not putting much money to work.

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

Puma Bio Bulls Win Monday's FDA Neratinib Review, Ahead of Wednesday's Advisory Panel Vote

The lack of "OMG" bombshells in the FDA's neratinib review are a Monday win for Puma bulls, and the stock is soaring.

Puma Biotechnology Announces Posting Of FDA Oncologic Drugs Advisory Committee Briefing Documents For Neratinib Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the U.

Puma Biotechnology Announces Publication Of Neratinib Abstract For The 2017 ASCO Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced the release of an abstract on its drug candidate PB272 (neratinib) that will be presented at the American Society of Clinical Oncology (ASCO)...

Puma Biotechnology Reports First Quarter 2017 Financial Results

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the first quarter ended March 31, 2017.

Puma Biotechnology To Present At Bank Of America Merrill Lynch 2017 Health Care Conference

Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H.

PUMA BIOTECHNOLOGY LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors Puma Biotechnology, Inc.

PUMA BIOTECHNOLOGY INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Puma Biotechnology, Inc. To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential securities fraud at Puma Biotechnology, Inc.

A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories

A Top Puma Bio Exec Resigns Ahead of FDA Panel, Analysts Defend With Conflicting Stories

The surprise exit of Puma's regulatory chief is sparking fears the FDA will deal harshly with the company's breast cancer drug neratinib.

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug

Over the past five years, the FDA has often used half-day sessions of the Oncologic Drugs Advisory Committee (ODAC) to administer public floggings to flawed cancer drugs.

Puma Biotechnology Announces FDA Advisory Committee To Review Neratinib For The Extended Adjuvant Treatment Of HER2-Positive Early Stage Breast Cancer

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, today announced that the U.

Figure 1: Treatment-Emergent Diarrhea, CONTROL Vs ExteNET (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from a Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American...

A Waterfall Plot Showing "% Change In Size Of Target Lesions" From Puma Biotechnology's FB-10 Trial In HER2-positive Metastatic Breast Cancer Is Attached. (Graphic: Business Wire)

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that interim results from the Phase Ib/II FB-10 clinical trial of Puma's investigational drug PB272 (neratinib) given in combination with the...

Puma Biotechnology Presents Results From The Phase II SUMMIT Trial Of PB272 For ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer At The 2017 AACR Annual Meeting

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that results from an ongoing Phase II clinical trial of Puma's investigational drug PB272 (neratinib) were presented at the 2017 American...

Puma Biotechnology Launches Expanded Access Program For PB272 (Neratinib) For U.S. Patients With HER2-Positive Breast Cancer Or HER2-Mutated Cancers

Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, has initiated an expanded access program (EAP) in the United States to provide its investigational therapy, PB272 (neratinib), to patients with...

Finding Bullish and Bearish Market Reversals

Finding Bullish and Bearish Market Reversals

These stocks are showing signs of changing direction.

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Biotechs Among 5 Stocks Setting Up for Major Breakouts

Here's how to rake in the profits off some potential big breakouts.

TheStreet Quant Rating: D- (Sell)